TerminatedNot applicableNCT01419587

Ketogenic Diet With Chemoradiation for Lung Cancer (KETOLUNG)

This study investigates if using a very low carbohydrate diet during combined chemotherapy and radiation therapy is safe and if it can be tolerated by lung cancer patients.

Checked against the public recordLast updated Jan 8, 2018 · Source: ClinicalTrials.gov

StatusTerminated
PhaseNot applicable
U.S. locations1
SponsorUniversity of Iowa
01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Not applicable
Sponsor
University of Iowa
Interventions being studied
Dietary Supplement: Ketogenic diet
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * Histologically or cytologically documented NSCLC. * Candidate for primary chemoradiation as decided by both medical and radiation oncology. * Cancer should be staged via AJCC as IIIA or IIIB. * Stage IV patients are considered provided they have a single non-CNS metastasis (that is amenable to treatment with radiation therapy). * Age ≥ 18 years * ECOG performance status 0-2 (Karnofsky \> 50%, see Appendix A). * Hypertensive medication should be initiated or increased for optimal blood pressure control according to standard public health guidelines prior to starting the ketogenic diet. * Patients must have normal organ and marrow function as defined below: * leukocytes ≥ 3,000/mm3 * absolute neutrophil count ≥ 1,500/mm3 * platelets ≥ 100,000/mm3 * total bilirubin \< 1.5 mg/dl * Hgb A1C \< or = to 8% * AST(SGOT) \< or = to 2 X institutional upper limit of normal * creatinine \< 1.5 X institutional upper limit of normal OR creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal. * Not pregnant. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Life expectancy of 3 or less months. * Prior thoracic radiotherapy. * Prior therapy, with the intent to treat, the current diagnosis of lung cancer. * Known G6PD (glucose-6-phosphate dehydrogenase) deficiency. * Systemic corticosteroids for any reason (inhaled corticosteroids are allowed). * Other investigational agents/therapy with the intention to treat the disease under study (observational or imaging trials are acceptable). * Uncontrolled diabetes defined as a hemoglobin A1C level \> 8% (therapeutic action is indicated at greater than 8%). * Diabetes is not exclusionary provided the patient is not maintained with either oral medications or insulin. * Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements as determined by study team members. * Pregnant or lactating women: The risks of radiation and chemotherapy to a fetus are well documented. Female and male patients of all ethnic groups will be eligible for treatment in these protocols.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Holden Comprehensive Cancer CenterIowa City, Iowa

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 8, 2018. Always confirm current availability with the study team.

View original record ↗